Neurocrine Biosciences (NBIX) has announced the launch of a new sprinkle formulation of INGREZZA capsules, designed for the treatment of adults suffering from tardive dyskinesia and chorea associated with Huntington's disease. The newly introduced INGREZZA SPRINKLE capsules are now accessible through the same network of specialty and locally affiliated pharmacies that distribute the traditional INGREZZA capsules. Notably, the company secured FDA approval for INGREZZA SPRINKLE on April 30.
Eiry Roberts, Chief Medical Officer at Neurocrine Biosciences, stated, "We aimed to provide this new option to patients and their caregivers, who wish to receive the benefits of INGREZZA treatment without facing the challenge of swallowing a capsule."
